ASH 2020 | 2020 CAR-T landscape: a revolutionary time
Aravind Ramakrishnan, MD, Sarah Cannon Blood Cancer Center at St. David’s South Austin Medical Center, Austin, TX, highlights the exciting aspects of CAR-T research and what new findings we should be on the lookout for. CAR-T cell therapy is a rapidly evolving area of research, with many scientific groups working on establishing the mechanisms behind recurrence and antigen loss. The main goal is to improve the safety of the treatment and make it accessible for a higher number of patients, by moving into an outpatient setting. Studies are currently being conducted into overcoming the immune checkpoints by changing the design of CAR-T cells. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research grants: Autolous, Incyte, Kadmon Pharmaceuticals, Kite Pharma, Novartis, Shire Development, Mana Therapeutics, Alpine Immune Sciences, Allovir
All payments made to Institution.
